Colorectal Neoplasms Clinical Trial
Official title:
A Randomized, Phase II Study of High-Risk Colorectal Cancer Patients (Stage IIIC) Treated With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX improves treatment, compared to standard of care (SOC), which is no further treatment.
Patients with Stage IIIC colon cancer have a 5-year survival rate of 28%. Stage III colon
cancer indicates that lymph nodes are involved.
Adjuvant FOLFOX only reduces the risk of recurrence of colorectal cancer by 40%, so almost
50% of patients still die from the disease. It is estimated that 50% of the patients relapse
within 18 months.
Because the prognosis of colorectal cancer is dependent on disease stage and because
metastatic disease is incurable, the concept of adding regorafenib to adjuvant FOLFOX has
been developed to allow patients with high-risk colorectal cancer the best chance of cure.
It is proposed to treat high-risk colorectal patients (Stage IIIC [T4a, N2a, M0] or
[T3-4a,N2b, M0], or [T4b, N1-N2, M0] per American Joint Committee on Cancer [AJCC] 7th ed.)
selected from the iKnowMed (iKM) electronic health records database who have completed
adjuvant FOLFOX. This feasibility study is to find the starting dose of regorafenib and
estimates that at least 75% of the patients will be able to tolerate the full dose of
regorafenib after receiving adjuvant FOLFOX.
Patients will be randomly assigned to regorafenib or to SOC (no treatment). In order to test
the best tolerated starting dose, the first 50 patients will receive regorafenib and will be
randomized 1:1 to either 120 mg by mouth (PO) or 160 mg PO. If the 120 mg dose is well
tolerated and the toxicities are not severe (Grade 2 or less) upon the completion of cycle 2,
the dose will be increased to 160 mg starting with Cycle 3. Registration and randomization of
patients will resume after the 26th then after the 50th patient completes 3 cycles of study
treatment. The Data Safety Monitoring Board (DSMB) will meet after the 26th patient completes
3 cycles of treatment and the second meeting will take place after the 50th patient completes
3 cycles. If needed, a third DSMB meeting will be scheduled. The remaining 214 patients will
be randomized 2:3 to the decided starting dose versus SOC.
In addition, evaluating the Texture (spatial variations in pixel intensity) in computed
tomography (CT) scans might help predict the risk of recurrence. Therefore, CT disks will be
sent to Imaging Endpoints Core Lab, Scottsdale, AZ, where the TexRAD platform (a software
algorithm) will be used for analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04552093 -
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
|
Phase 2/Phase 3 | |
Completed |
NCT04192565 -
A Prospective Investigation of the ColubrisMX ELS System
|
N/A | |
Completed |
NCT05178745 -
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
|
||
Recruiting |
NCT03561350 -
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
|
||
Recruiting |
NCT06128798 -
Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery.
|
N/A | |
Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
Completed |
NCT03631407 -
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
|
Phase 2 | |
Withdrawn |
NCT04192929 -
Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy
|
N/A | |
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Terminated |
NCT02842580 -
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02889679 -
Underwater Resection of Non-pedunculated Colorectal Lesions
|
N/A | |
Completed |
NCT02564835 -
Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer
|
N/A | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT02149108 -
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
|
Phase 3 | |
Completed |
NCT02599103 -
The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects
|
N/A | |
Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
Completed |
NCT01669109 -
Hatha Yoga for Patients With Colorectal Cancer
|
N/A | |
Recruiting |
NCT01428752 -
Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer
|
N/A | |
Completed |
NCT01978717 -
General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer
|
N/A | |
Completed |
NCT01877018 -
Colorectal Cancer Screening in Primary Care
|
N/A |